GlassScriptPhysician profile
Kayla Briann Beining
NPI 1427529551
$3,851.34
in general payments reported to CMS, 2019-2025
33 companies · $383 in 2025
The $383 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $732 · 2022: $734 · 2023: $965 · 2024: $1,038 · 2025: $383.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,386.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,385.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $681.11 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $386.94 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Glaxosmithkline, LLC. | $356.12 | 2021-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $207.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $204.34 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Novartis Pharmaceuticals Corporation | $202.81 | 2021-2023 | |
| Novo Nordisk INC | $175.10 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $137.99 | 2022-2023 | |
| Amgen INC. | $127.79 | 2021-2025 | Repatha, Repatha, Otezla |
| Biohaven Pharmaceuticals, INC. | $126.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $125.00 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $116.76 | 2023 | Lifevest |
| Pfizer INC. | $101.43 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $100.76 | 2022-2024 | Verquvo, Gardasil, Gardasil 9 |
| Neurocrine Biosciences, INC. | $94.56 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $83.21 | 2022-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $74.97 | 2022 | |
| Dexcom, INC. | $65.30 | 2021-2023 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $62.32 | 2021-2024 | Rexulti |
| Exact Sciences Corporation | $59.70 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $52.26 | 2023 | Quviviq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.22 | 2022-2023 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.73 | 2025 | Caplyta |
| Inogen, INC. | $39.08 | 2022-2023 | Inogen At Home Stationary Concentrator |
| Nestle Healthcare Nutrition INC. | $31.84 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $27.62 | 2024 | |
| Xeris Pharmaceuticals, INC. | $23.19 | 2024 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $21.19 | 2021 | |
| Cipher Pharmaceuticals US LLC | $20.07 | 2025 | Natroba, Spinosad |
| Ucb, INC. | $17.03 | 2023 | Briviact |
| Antares Pharma, INC. | $15.71 | 2022 | |
| Phathom Pharmaceuticals, INC. | $15.39 | 2025 | Voquezna |
| Grt US Holding, INC. | $12.13 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Beining listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.